P. Hegde
University of California, San Francisco · 14 works · 165 citations · h-index 5
Top works
- MA 05.09 Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC
- Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)
- Abstract P2-09-13: Molecular characterization of tumors from metastatic TNBC patients treated with atezolizumab (atezo)
- Inhibition of Pd-L1 By Mpdl3280A Leads to Clinical Activity in Pts with Metastatic Urothelial Bladder Cancer (Ubc)
- Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK)
- Clinical Efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study
- Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in non-small cell lung carcinoma patients responding to atezolizumab treatment
- 2877 Characterization of PD-L1 expression and immune cell infiltration in Nasopharyngeal Cancer (NPC)
- The SP142 PD-L1 IHC assay for atezolizumab (atezo) reflects pre-existing immune status in NSCLC and correlates with PD-L1 mRNA
- Atezolizumab in combination with bevacizumab enhances migration of antigen-specific T-cells in metastatic renal cell carcinoma
- Vascular and lymphatic phenotype of HER2+ breast cancer.
- 440 Characterization of tumor immune biomarker landscape and its clinical associations in non-small-cell lung carcinoma (NSCLC)
- Pan-cancer genomic analysis of MSI-H tumors reveals commonly altered pathways
- Prevalence of Incidental Detection of Other Malignancies in Structured Early Diagnosis of Lung Cancer Program